Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 4/20 | 1.00 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 1.00 |
| ▸ | ORAI2 | Q96SN7 | 3/20 | 1.00 |
| ▸ | ORAI3 | Q9BRQ5 | 3/20 | 1.00 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8161029 | 0.81 | TRPV6 (0.65) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL7796734 | 0.75 | ORAI1 (0.60) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL4264054 | 0.73 | ORAI1 (0.57) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL14187127 | 0.71 | ORAI1 (0.55) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL500599 | 0.71 | TRPV6 (0.55) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL13476067 | 0.69 | ORAI1 (0.52) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL7800329 | 0.69 | TSHR (0.56) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL6911660 | 0.69 | ORAI1 (0.52) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL7270858 | 0.69 | ORAI1 (0.52) | TRPV6ORAI1ORAI2ORAI3PCSK9 | |
| SCHEMBL7461066 | 0.69 | ORAI1 (0.52) | TRPV6ORAI1ORAI2ORAI3PCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239814-A1 | Complexes Of CU(I) As Antitumor Agents | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2024-07-18 | — | — | US | claimed |
| CN-117835181-A | Unmanned ship data transmission method based on data fusion | 中国船舶集团有限公司系统工程研究院 | 2024-04-05 | — | — | CN | claimed |
| CN-117417541-A | Preparation method of 2D halogen bond organic framework XOF, preparation method of chiral supramolecular halogen bond organic framework and application | 武汉大学 | 2024-01-19 | — | — | CN | claimed |
| CN-115179280-A | Reward shaping method based on magnetic field in mechanical arm control for reinforcement learning | 南京大学 | 2022-10-14 | — | — | CN | claimed |
| US-20170128475-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-11 | — | — | US | claimed |
| US-20140148413-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-05-29 | — | — | US | claimed |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2013-08-08 | — | — | US | claimed |
| EP-2585109-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | The General Hospital Corporation (US) | 2013-05-01 | — | — | EP | claimed |
| WO-2012012498-A9 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-04-05 | — | — | WO | claimed |
| WO-2012012498-A2 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-01-26 | — | — | WO | claimed |
| WO-2011163308-A2 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING ORGAN INJURY AND/OR DYSFUNCTION | THE GENERAL HOSPITAL CORPORATION (US) | 2011-12-29 | — | — | WO | claimed |
| EP-1620905-A1 | ELECTROLUMINESCENT BORON COMPLEXES | NUKO 70 Limited (GB) | 2006-02-01 | — | — | EP | claimed |
| WO-2004084325-A1 | ELECTROLUMINESCENT BORON COMPLEXES | NUKO 70 LIMITED (GB) | 2004-09-30 | — | — | WO | claimed |
| US-6353071-B1 | DESICCATING MIXTURE OF ALUMINOXANE AND SOLVENT TO PRODUCE SOLID, MIXING WITH SOLVENT, CONTACTING SECOND MIXTURE WITH INSOLUBLIZATION AGENT TO PRODUCE ALUMINOXANE COMPOSITION, COMBINING WITH TRANSITION METAL CATALYST, POLYMERIZING OLEFIN | PHILLIPS PETROLEUM COMPANY | 2002-03-05 | — | — | US | claimed |
| US-6096915-A | Processes to produce organo-aluminoxane compositions | PALACKAL SYRIAC J (US) | 2000-08-01 | — | — | US | claimed |
| JP-5213760-A | — | — | None | — | — | JP | disclosed |
| CN-116790617-B | Gene mutant for reducing leaf water loss rate and application thereof | 云南省烟草农业科学研究院 | 2026-05-12 | — | — | CN | disclosed |
| US-5196478-A | Polystyrene, assays | EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) | 1993-03-23 | — | — | US | disclosed |
| EP-0439585-A1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS. | EPIPHARM ALLERGIE SERVICE (AT) | 1991-08-07 | — | — | EP | disclosed |
| WO-1991002768-A1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS | EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) | 1991-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239814-A1 | Complexes Of CU(I) As Antitumor Agents | C1S, C9, C1R | TRPV6 4154/4885ORAI1 421/4885ORAI2 3097/4885 |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | TRPV1, TRPC4, TRPC3 | TRPV6 17/4885ORAI1 65/4885ORAI2 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.